Home › Acute Myeloid Leukemia › New York › New Rochelle
Acute Myeloid Leukemia clinical trials in New Rochelle, NY
13 studies for Acute Myeloid Leukemia are looking for participants at sites in and around New Rochelle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- North Shore University Hospital, Manhasset · 9 mi away
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
RecruitingPhase 1
- Memorial Sloan Kettering Westchester, Harrison · 5 mi away
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Memorial Sloan Kettering Westchester, Harrison · 5 mi away
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Memorial Sloan Kettering Westchester, Harrison · 5 mi away
- North Shore University Hospital, Manhasset · 9 mi away
A Study of CRD3874-SI in People With Leukemia
RecruitingPhase 1
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison · 5 mi away
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- North Shore University Hospital, Manhasset · 9 mi away
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
RecruitingPhase 2
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison · 5 mi away
A Study of Revumenib and Mezigdomide in People With Leukemia
RecruitingPhase 1/2
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison · 5 mi away
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RecruitingPhase 1
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison · 5 mi away
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
RecruitingPhase 1
- Memorial Sloan Kettering Westchester, Harrison · 5 mi away
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
RecruitingPhase 1
- Memorial Sloan Kettering West Harrison (Limited Protocol Activities), Harrison · 5 mi away
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
RecruitingPhase 1
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison · 5 mi away
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
RecruitingPhase 2
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison · 5 mi away
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Seattle, WA41 studies
- Baldwin Park, CA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA31 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Other studies in New Rochelle
- Breast Cancer38 studies
- Non-Small Cell Lung Cancer18 studies
- Prostate Cancer16 studies
- Multiple Myeloma14 studies
- Bladder Cancer11 studies
- Lung Cancer11 studies
- Endometrial Cancer11 studies
- Metastatic Cancer10 studies
- Cancer (all types)10 studies
- Ovarian Cancer9 studies
- Cardiovascular Disease8 studies
- Pancreatic Cancer8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.